Bear market slows PepGen's roll, causing DMD-focused biotech to price below range
A month after PepGen transitioned to a clinical-stage company with its Duchenne muscular dystrophy trial in Canada, the Boston biotech is debuting on Wall Street.
But its Nasdaq entrance was subdued Friday with a $12 pricing $PEPG, falling below the penciled-in $13 to $15 range. And Bausch Health’s eyecare products spinout, Bausch + Lomb, also faced reality with a launch below its range, at $18 $BLCO instead of the targeted $21 to $24 it wanted.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.